Location: Solmed Polyclinic (Zagreb)
Study Drug: Patients will receive standard biological therapy with vedolizumab or vedolizumab biosimilar.
Main Inclusion Criteria: Patients aged 18 and older with an official diagnosis of ulcerative colitis who, with at least one previous line of treatment (either conventional or biological therapy), have symptoms of active disease.
Status: In preparation
Start of patient enrollment: September 2024
Planned completion of patient enrollment: June 2025